Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan

Figures & data

Table I. Patient demographics and characteristics.

	Zofenopril	Losartan	p‐value
n	165	162
Gender (male/female)	80/85	68/94	0.981
Age (years)	57.8±9.7	57.9±9.4	0.273
Body mass index	28.2±3.0	28.6±3.1	0.242
Previously treated/untreated	126/39	116/46	0.327

Shown are actual numbers or means±SD. Statistical comparison by Student's t‐test or chi‐square test.

Table II. Sitting systolic and diastolic blood pressures in zofenopril and losartan treated patients during 12 weeks of follow‐up.

	Zofenopril (SBP/DBP)	Losartan (SBP/DBP)	p‐value
Baseline	158.1±12.4/98.8±3.2	157.9±12.0/99.0±3.0	0.888/0.544
Week 4	141.3±13.9/85.9±7.8	144.7±16.1/88.5±8.1	0.058/0.006
Week 8	141.2±13.1/84.9±8.0	141.2±14.7/86.2±8.0	0.987/0.170
Week 12	139.7±14.6/84.3±8.1	139.6±15.0/85.8±8.2	0.985/0.117

Shown are means±SD of blood pressure values in mmHg from the 12 weeks intention‐to‐treat population (zofenopril 30–60 mg od = 150; losartan 50–100 mg od = 139). Dose up‐titration was optional in non‐responders at week 4. SBP, systolic blood pressure; DBP, diastolic blood pressure. Statistical comparison between treatments by ANOVA. SBP and DBP reductions at weeks 4, 8 or 12 versus baseline value all p<0.001.

Table III. Diastolic blood pressures during the 12 weeks follow‐up after zofenopril and losartan treatment in responder and non‐responder patient groups.

Responders – no dose increase	Zofenopril 30 mg (DBP)	Losartan 50 mg (DBP)	p‐value
Baseline	98.2±2.7	98.5±2.8	0.535
Week 4	81.6±4.9	83.4±5.8	0.027
Week 8	82.2±7.1	83.0±6.8	0.455
Week 12	81.4±6.8	83.4±6.9	0.046
Non‐responders – dose increase	Zofenopril 60 mg (DBP)	Losartan 100 mg (DBP)	p‐value
Baseline	100.1±3.9	99.8±3.2	0.716
Week 4	94.8±4.7	95.5±5.1	0.482
Week 8	90.5±6.9	90.6±7.5	0.950
Week 12	90.6±6.9	89.2±8.8	0.372

Shown are means±SD of blood pressure values in mmHg from the 12 weeks intention‐to‐treat population (zofenopril – 123 responders and 27 non‐responders; losartan – 111 responders and 28 non‐responders). Zofenopril was given 30–60 mg od and losartan 50–100 mg od. In non‐responders, the higher zofenopril dose (60 mg od) or the higher losartan dose (100 mg od) could be given at week 4. DBP, diastolic blood pressure. Statistical comparison between treatments by ANOVA. DBP reductions in responders and non‐responders at weeks 4, 8 or 12 versus the respective baseline value all p<0.001.

Table IV. Comparisons of clinic blood pressure (BP) measurements by sphygmomanometry and home BP measurements (by the patient) using an Omron device at 12 weeks.

	Zofenopril	Losartan	p‐value
Diastolic blood pressure (mmHg)
Baseline (sphygmomanometer)	98.8±3.1	99.0±3.0
After 12 weeks
Sphygmomanometer	84.5±7.9	85.8±8.2	0.116
Omron during visit	86.8±9.6	87.8±10.8	0.254
Omron 2–3 days before visit	80.1±8.4	81.9±8.6	0.206
Systolic blood pressure (mmHg)
Baseline (sphygmomanometer)	157.9±12.4	157.9±12.0
After 12 weeks
Sphygmomanometer	139.4±14.3	139.6±15.0	0.838
Omron during visit	142.7±18.5	141.2±19.0	0.936
Omron 2–3 days before visit	129.7±15.6	134.4±15.4	0.027

Values at baseline in zofenopril‐ and losartan‐treated patients, before and during the scheduled visits as well as measurements on working days, holidays, and before and after noon. Shown are means±SD of blood pressure values in mmHg from the 12 weeks intention‐to‐treat population (zofenopril 30 mg od = 150; losartan 50 mg od = 139). Statistical comparison between treatments by ANOVA. Systolic and diastolic blood pressure reductions at week 12 versus baseline value all p<0.001.